Oryzon Genomics (BME: ORY)

Currency in EUR

Last close As at 07/06/2023


0.00 (0.00%)

Market capitalisation


Spanish biotech Oryzon Genomics is focused on epigenetics. Iadademstat is being explored for acute leukaemias, small-cell lung cancer (SCLC) and neuroendocrine tumours. Central nervous system (CNS) asset Vafidemstat has completed several Phase IIa trials and a Phase IIb trial in borderline personality disorder is now the lead study.

Oryzon is among the leading clinical-stage drug developers with a second generation of epigenetic therapeutics, which have greater selectivity and potentially favourable safety/efficacy profile than the first generation HDAC inhibitors.



Equity Analyst

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Key Management

  • Carlos Buesa


Balance Sheet

Forecast net debt (€m)


Forecast gearing ratio (%)


Share Price Performance

Price Performance
% 1M 3M 12M
Actual (3.5) (11.4) (15.4)
Relative (5.2) (9.5) (19.7)
52 week high/low €3.0/€2.0


Oryzon develops small molecule inhibitors for epigenetic targets. The two lead drugs are iadademstat for oncology and vafidemstat for CNS indications (both are LSD1 inhibitors, an epigenetic target). In oncology, positive top-line data have been reported from the ALICE trial in acute myeloid leukaemia (AML) while new trials FRIDA in AML (first patient dosed in Q123) and STELLAR in SCLC could potentially be pivotal, with the FDA having now granted orphan drug designation for iadademstat in AML and SCLC. The FRIDA study represents one of Oryzon’s key strategic priorities. In CNS, vafidemstat is being evaluated in two Phase IIb trials, PORTICO in borderline personality disorder, which reported positive interim results in Q123 with top-line data expected in early FY24, and EVOLUTION in schizophrenia. Oryzon is also hoping to register vafidemstat in its Phase I/II HOPE study targeting Kabuki syndrome.

Y/E Dec Revenue (€m) EBITDA (€m) PBT (€m) EPS (fd) (c) P/E (x) P/CF (x)
2021A 10.6 (6.9) (7.2) (8.83) N/A N/A
2022A 15.7 (5.3) (6.4) (7.26) N/A N/A
2023E 17.3 (3.7) (4.2) (3.27) N/A N/A
2024E 19.0 (9.3) (10.0) (13.64) N/A N/A

Further insights


Analyst of the week

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Read latest

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free